Ildong Pharmaceutical Co., Ltd.

▎药明康德内容团队编辑 本期看点 1. 盐诱导激酶（SIK）抑制剂OMX-0407在1a期临床试验中使1名对多种化疗药物耐药的晚期实体瘤患者的肿瘤完全消失。 2. 治疗帕金森病的变构小分子疗法GT-02287的早期临床结果积极，它能够穿越血脑屏障并与靶标结合，同时展现良好的安全性与耐受性。 药明康德内容团队整理 OMX-0407：公布1a期临床试验数据 iOmx Therapeutics公司宣布，其潜在“first-in-class”的选择性SIK抑制剂OMX-0407的1a期临床试验已顺利完成，即将启动1b期临床试验。OMX-0407能够通过调控酪氨酸激酶信号直接干扰肿瘤细胞增殖。除了这种直接作用方式外，OMX-0407还能通过增强肿瘤坏死因子等死亡受体配体引发的肿瘤细胞凋亡，重塑肿瘤微环境。 初步数据显示，OMX-0407单药治疗是安全且耐受性良好的。OMX-0407对经过多次治疗的晚期实体瘤患者有抗癌活性。其中，一名对多种化疗药物耐药的患者达到了持久的完全缓解（CR），所有肿瘤病灶均消失。此外，生物标志物分析表明，循环血细胞中存在确凿的药理活性证据。 GT-02287：公布1期临床试验数据 Gain Therapeutics宣布其用于治疗帕金森病的在研变构小分子GT-02287在1期试验中获得积极结果。GT-02287是一种口服变构蛋白调节剂，具有可穿越血脑屏障的小分子量。该药物可恢复溶酶体蛋白酶葡萄糖脑苷脂酶（GCase）的功能，该酶由于GBA1基因突变（与帕金森病相关的最常见遗传异常）或其他与年龄相关的压力因素而发生错误折叠和受损。 在帕金森病的临床前模型中，GT-02287恢复了GCase酶功能，减少了聚集的α突触核蛋白、神经炎症和神经元死亡，提高了多巴胺水平，改善动物的运动功能和认知能力，可能具有减缓帕金森病进展的潜力。此外，GT-02287显著降低了血浆神经丝轻链（NfL）水平，这是一种神经退行性疾病的生物标志物。 此次公布的结果显示，GT-02287存在于受试者的脑脊液中，并与外周靶标相结合。在具良好安全性与耐受性的口服剂量下，该药物的血浆水平达到治疗性水平，并可抵达中枢神经系统并与靶标相结合，显示GT-02287是潜在的帕金森病疗法，无论患者是否具有GBA1突变。Gain Therapeutics预计在今年第四季度启动该疗法的1b期临床试验。 Exidavnemab：公布1期临床试验数据 BioArctic公司公布了其靶向聚集的α突触核蛋白的单克隆抗体exidavnemab的两项与艾伯维合作开展的1期研究的积极结果。该候选药物旨在治疗帕金森病等神经退行性疾病。结果显示，85名接受了exidavnemab静脉注射或皮下注射的受试者对治疗的总体耐受性良好。Exidavnemab的半衰期约30天，对聚集的α突触核蛋白具有高亲和力和选择性，这是其在大脑中保持高靶点结合力的关键。 OCU410ST：1/2期临床试验完成第三个队列的给药 Ocugen公司宣布，其针对Stargardt病开发的候选基因疗法OCU410ST的1/2期临床试验已完成第三个队列的给药。OCU410ST利用腺相关病毒（AAV）递送平台在视网膜递送RORA基因，可调节与Stargardt病相关的通路，例如脂褐素形成、氧化应激、炎症、细胞存活网络等。 FTX-101：IND申请获得FDA许可 Find Therapeutics公司宣布，美国FDA已经批准了FTX-101的IND申请，该公司计划在2024年第四季度启动FTX-101在健康志愿者中的1期临床研究。FTX-101是一种潜在“first-in-class”的髓鞘再生剂，旨在恢复慢性视神经病变患者的视力。FTX-101是一种经过合理设计的治疗肽，靶向Plexin A1和Neuropilin 1。Plexin A1和Neuropilin 1是大脑中存在的一种受体复合物，已被证明参与了少突胶质细胞前体细胞迁移和分化成髓鞘化少突胶质细胞的过程。临床前数据显示，FTX-101在脱髓鞘模型中具有很强的髓鞘修复活性。 ID110521156：IND申请获得韩国食品药品安全部许可 Yunovia公司宣布，韩国食品药品安全部（MFDS）已批准其口服的小分子GLP-1受体激动剂ID110521156用于治疗糖尿病和肥胖的IND申请，可启动1期多剂量递增（MAD）研究。ID110521156具有与GLP-1激素相同的作用，包括促进体内胰岛素的合成和分泌、降低血糖水平、调节胃肠道运动以及抑制食欲。作为一款小分子疗法，ID110521156与当前的标准治疗肽类注射剂相比，具有制造方便和使用简便等差异化特性。 Yunovia已于2024年7月完成了ID110521156的1期单剂量递增研究，包括食物效应研究。结果显示，ID110521156的耐受性良好，有望作为一种每日一次疗法。 MB097、MB310：获批在欧盟和英国启动1b期临床试验 Microbiotica公司宣布，其开发的两款活体生物治疗产品（LBP）MB097和MB310已获得监管部门的批准，可以在选定的欧盟国家和英国启动临床研究。MB097是一种每日一次的口服LBP，由九种细菌菌株组成，能够提供免疫检查点抑制剂（ICI）反应所需的微生物组信号，旨在提高ICI的疗效。临床前研究表明，MB097能够刺激免疫系统的核心途径，激活细胞毒性T淋巴细胞和自然杀伤细胞，使其能够杀死肿瘤细胞。此次开展的1b期研究将评估MB097联用PD-1抑制剂pembrolizumab治疗晚期黑色素瘤的安全性和疗效。 MB310是从健康供体中鉴定出的一个明确的微生物群落。临床前研究表明，MB310能够通过至少三种独立的机制发挥对溃疡性结肠炎的治疗作用，包括促进受损肠道上皮屏障的愈合，调节炎症和免疫调节细胞因子的平衡，以及诱导调节性T细胞反应。此次开展的1b期研究将评估MB310治疗溃疡性结肠炎的安全性和疗效。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放 参考资料（可上下滑动查看） [1] Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy. Retrieved August 30, 2024, from https://ir.ocugen.com/news-releases/news-release-details/ocugen-announces-completion-dosing-subjects-stargardt-disease [2] Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology. Retrieved August 30, 2024, from https://www.prnewswire.com/news-releases/study-results-from-phase-1-studies-with-exidavnemab-published-in-the-journal-of-clinical-pharmacology-302231302.html [3] Find Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Study of FTX-101 for the Treatment of Chronic Optic Neuropathy. Retrieved August 30, 2024, from https://www.prnewswire.com/news-releases/find-therapeutics-announces-fda-clearance-of-ind-application-for-a-phase-1-study-of-ftx-101-for-the-treatment-of-chronic-optic-neuropathy-302229869.html [4] Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease. Retrieved August 29, 2024, from https://www.gaintherapeutics.com/newsroom/press-releases/press-releases-2024/ainherapeuticsnnouncesositiveoplineesultsfromth20240829043502 [5] iOmx Therapeutics Initiates Phase Ib with OMX-0407. Retrieved August 30, 2024, from https://www.globenewswire.com/en/news-release/2024/08/22/2933999/0/en/iOmx-Therapeutics-Initiates-Phase-Ib-with-OMX-0407.html [6] AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema. Retrieved August 30, 2024, from https://aiviva.com/2024/08/aiviva-biopharma-completes-enrollment-in-a-phase-1-clinical-trial-of-aiv007-for-age-related-macular-degeneration-and-diabetic-macular-edema/ [7] First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company. Retrieved August 30, 2024, from https://ir.lixte.com/news-events/press-releases/detail/115/first-patient-dosed-with-lixtes-lb-100-in-new-clinical-trial-to-treat-colorectal-cancer-collaborating-with-nki-supported-by-major-pharma-company [8] ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051. Retrieved August 30, 2024, from https://www.globenewswire.com/news-release/2024/08/27/2935974/0/en/ENA-Respiratory-Progresses-Phase-Ib-Study-of-its-Dry-Powder-Formulation-of-Intranasal-Innate-Immunomodulator-INNA-051.html [9] Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist. Retrieved August 30, 2024, from https://www.prnewswire.com/news-releases/yunovia-announces-ind-approval-by-the-mfds-to-initiate-phase-1-mad-study-for-the-small-molecule-glp-1-agonist-302232393.html [10] Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies. Retrieved August 30, 2024, from https://www.globenewswire.com/news-release/2024/08/27/2935969/0/en/Microbiotica-s-Microbiome-Medicines-in-Melanoma-and-Ulcerative-Colitis-Gain-Regulatory-Approvals-in-EU-and-UK-for-Phase-1b-Studies.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新

SEOUL, South Korea, Aug. 27, 2024 /PRNewswire/ -- Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has cleared the IND application of Phase 1 Multiple Ascending Dose (MAD) study for ID110521156, an orally available small molecule GLP-1 agonist being developed for obesity and diabetes following the successful completion of the Phase 1 Single Ascending Dose (SAD) study. Phase 1 MAD study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) characteristics of ID110521156 following repeated administration and stepwise increase in dose. Previously, Yunovia not only confirmed the drug's effectiveness related to insulin secretion and blood glucose control, but also, its superior tolerability compared to other drugs in the same class through preclinical efficacy and toxicity evaluations in the recently completed Phase 1 SAD study. ID110521156 is a GLP-1 (glucagon-like peptide-1) receptor agonist that plays the same role as the GLP-1 hormone which is involved in the synthesis and secretion of insulin in the body, reduction of blood glucose level, regulation of gastrointestinal tract movements, and appetite suppression. Since ID110521156 is a small molecule compound, the Company's strategy is to develop it as an orally administrable drug for diabetes and obesity with differentiated attributes such as superior manufacturability and ease of use compared to peptide injections, the current standard of care. A Yunovia representative emphasized, "ID110521156 is the only small molecule based new drug in the clinical stage among all GLP-1 receptor agonists in Korea, and even by the global market standards, it falls within the group of GLP-1 receptor agonists whose development status is relatively advanced." The Company representative further stated, "We had been communicating with potential partner companies from the early development stage where their feedback from the perspective of the needs of the 'GLP-1 market', had been reflected in the designing of the SAD and MAD studies" Based on our continuing dialogue with them, we will proceed with further development of ID110521156 and, pursue global out-licensing. About ID110521156 ID110521156 is an orally available small molecule agonist of the GLP-1 receptor. Yunovia completed its Phase I SAD, including food effect study, in July 2024. ID110521156 was well tolerated and demonstrated potential as a once-daily drug with a sustained PK profile. The company plans to collect PD data, including continuous glucose monitoring and body weight changes, as exploratory endpoints from a 4-week MAD study. About Yunovia Yunovia was established in 2023 as a split-off from Ildong pharmaceutical to release the full potential value of global, innovative drug pipeline and to maximize the R&D productivity for accelerated drug development. Yunovia's R&D pipeline includes more than 20 innovative programs at various development stages for various therapeutic areas. With its small molecule R&D expertise and pipeline, including 3+ clinical programs, Yunovia will strive to grow as a leading innovator for life changing therapeutics. For more information, please visit . CONTACT: Hyang Choi, Business Development Team 2, Deputy General Manager, +82-2-526-3288, [email protected] SOURCE Yunovia

DONGTAN, KOREA, June 10, 2024 - iLeadBMS, a new drug R&D company under Ildong Pharmaceutical Group, announced on the 10th that it presented in vivo study results on its liver fibrosis treatment candidate 'IL1512' at the European Association for the Study of the Liver (EASL) 2024, held in Milan, Italy, from June 5th to the 8th. IL1512 is an oral CXCR7 agonist and is classified as a first-in-class drug, a type of drug that has never been developed for the same therapeutic indication previously. Last month, iLeadBMS presented the efficacy results of this drug for idiopathic pulmonary fibrosis (IPF) at the American Thoracic Society (ATS 2024), and this time around it announced the anti-fibrotic effects of the drug in the liver. CXCR7 is a G protein-coupled receptor that binds to chemokine ligands CXCL11 and CXCL12, targeting various pathways related to fibrosis such as fibroblast activation, inflammation, tissue repair, and angiogenesis. This makes it an ideal therapeutic target for treating fibrotic diseases. Given that CXCR7 agonists exerts their anti-fibrotic properties through a novel mechanism, iLeadBMS plans to develop anti-fibrotic drugs to treat fibrosis in various organs including but not limited to the lungs, liver, heart, kidneys, and skin, and is also considering utilizing the expedited review and Orphan Drug Designation (ODD) pathways offered by the FDA. Based on the presentation at the conference, iLeadBMS has confirmed the anti-fibrotic effects of IL1512 in the well-established CCl4 (carbon tetrachloride) liver fibrosis model with oral administration of the test article. Significant improvements in various anti-fibrotic indicators (col 1a1, hydroxyproline content, TGF-beta) were observed compared to the placebo. The presentation emphasized that IL1512, with its novel mechanism targeting CXCR7, demonstrated direct anti-inflammatory effects on the liver and improvement in fibrosis. Additionally, it highlighted that IL1512 showed either superior or at minimum, comparable efficacy and safety profiles compared to Elafibranor, the comparator drug. Based on these research results, iLeadBMS has identified preclinical candidate molecules with even greater improvements over IL1512 and, plans to start GLP (Good Laboratory Practice) toxicology studies in the second half of this year. About iLeadBMS Established in 2020, iLeadBMS specializes in the discovery and development of novel drugs, with an R&D pipeline targeting fibrotic diseases, protease inhibitors, solid tumors, and neurodegenerative diseases. For more information on iLeadBMS, please visit: